Compare CVS Health Corp (CVS) vs New York Times Co (NYT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs New York Times Co — how do they compare? CVS Health Corp trades at $93.7 (market cap $122.36B), while New York Times Co trades at $63.74 (market cap $10.45B). The key difference: CVS Health Corp is far larger — about 11.7× New York Times Co's market cap, and CVS Health Corp pays the higher dividend (2.78%). Which is the better fit depends on your goals.
| CVS | NYT | |
|---|---|---|
Market Cap | $122.36B | $10.45B |
Sector | Health | Media |
52-Week High | $110.60 | $85.86 |
52-Week Low | $65.51 | $54.66 |
Enterprise Value | $184.71B | $9.85B |
Dividend Yield | 2.78% | 1.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $95.70, down 0.54% on the day, with a bearish technical signal and key support at $95. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.58 versus $1.87 expected, and raised its full-year guidance. Revenue growth remains robust, reaching $402.07 billion in 2025, though net income margin compressed to 1.18%. Analyst sentiment is overwhelmingly positive with a consensus price target of $115.00.
The outlook for CVS is cautiously optimistic, driven by operational improvements in its Aetna segment and raised cash flow guidance. Investment opportunities include potential upside to the consensus target, but risks involve margin pressures, regulatory changes impacting pharmacy benefits in 2027, and high debt levels. The stock's current valuation at a P/E of 25.25 may limit near-term gains if earnings growth slows.
The New York Times (NYT) stock trades at $63.54, down 1.9% recently, with a bearish technical signal from moving averages but neutral oscillators. Fundamentally, the company shows strong profitability with a 13.19% net income margin and consistent earnings beats, including Q2 2026 EPS of $0.69 versus $0.663 expected. Revenue growth is steady, reaching $2.82B in 2025, though digital subscriber additions have moderated, contributing to near-term stock weakness.
Outlook remains mixed; analyst consensus targets $77.50 with 29% buy ratings, but slower subscriber growth and high valuation (P/E 26.48) pose risks. Opportunities include digital expansion and pricing power, while risks involve competition and economic sensitivity. The stock's current level near support at $63 may attract value-oriented investors if fundamentals hold.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →
